Abstract. PTEN acts as a phosphatidylinositol phosphatase with a possible role in the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Mutations in PTEN are frequent and their presence is associated with poor prognosis in breast cancer, which is the most common type of non-cutaneous malignancy in females. Delivery of the tumor suppressor PTEN gene represents a powerful strategy for breast cancer therapy, but a present limitation of gene therapy is the ability to deliver sufficient quantities of active proteins to target cells. The capacity of HSV-1VP22 fusion proteins to spread from the primary transduced cell to surrounding cells could improve gene therapeutics, particularly in cancer. To assess the potential efficacy of VP22 as a gene therapy for breast cancer, expression vectors for N-and C-terminal PTEN-VP22 fusion proteins were constructed. VP22-mediated intercellular transport and antitumor efficacy in BT549 (PTEN-null) breast tumor cells were investigated. The results showed that PTEN-VP22 has the same spreading abilities as VP22. In cell proliferation and apoptosis assays, PTEN-VP22 gene transfer induces a stronger anti-proliferative effect and apoptotic activity compared with PTEN gene transfer alone. In addition, VP22 enhanced the PTEN-mediated decrease in the level of phosphorylated AKT. The results show that PTEN-VP22 can spread in vitro and PTEN-VP22 gene induces significantly greater antitumor activity than the PTEN gene alone. This study confirms the utility of VP22-mediated delivery in vitro and suggests that PTEN-VP22 may have applications in breast cancer gene therapy.
Introduction
Breast cancer is the most common type of non-cutaneous malignancy in females and is the second (only to lung carcinoma) most common cause of cancer-related mortality (1) . In the United States, females have an estimated 12% lifetime risk of being diagnosed with breast cancer; the risk of breast cancer-related mortality is estimated at 2.82%, even after optimal treatment (2) . Conventional anticancer therapeutics have reached the limit of their utility, necessitating a novel therapeutic strategy to improve outcomes. PTEN (phosphatase and tens in homolog on chromosome ten) is a tumor suppressor and encodes a dual-specificity phosphatase (3) . Its primary substrate is the second messenger phosphatidylinositol 3,4,5 trisphosphate (PIP3) (4) . PTEN antagonizes the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and affects cellular processes including growth, proliferation and survival (5) . PTEN is mutated in numerous types of cancer; the high frequency of monoallelic mutations of PTEN has been demonstrated in endometrial carcinoma, glioblastoma, and prostate, breast, colon and lung tumors (6) . Complete loss of PTEN is generally associated with advanced cancer and metastases in endometrial cancer and glioblastoma (6) .
In breast cancer, a recent study revealed that PTEN loss is a common event in breast cancers caused by BRCA1 mutations (7) . PTEN has also been investigated for its prognostic power in several types of human malignancy. Loss of PTEN expression is associated with the poor survival of patients with basal-like breast cancer (8) , and data from preclinical and clinical studies implicate PTEN loss in constitutive PI3K/AKT/mTOR signaling and de novo resistance to Herceptin 2-targeted therapy (9) . Delivery of the tumor suppressor PTEN gene represents a powerful strategy for breast cancer therapy, although virus-mediated gene therapy is associated with safety problems and non-virus-mediated gene therapies are inefficient (10) .
Previous studies have shown that VP22 proteins from HSV-1 have the capacity to cross cell membranes (11) . In addition, VP22 proteins are capable of transducing heterologous proteins, such as p53, p27, CD, GFP and Hsp70 (12) , across the cell membrane, although the delivery mechanisms have not been fully characterized. It was hypothesized that introducing VP22 proteins as well as PTEN may improve cell penetration and increase antitumor efficacy. In this study, VP22 was conjugated VP22 mediates intercellular trafficking and enhances the in vitro antitumor activity of PTEN to the C terminus of PTEN and the growth-inhibitory activity of the fused proteins was observed in a breast carcinoma cell line. ) (Cell Signaling Technology Inc., Beverly, MA, USA) polyclonal antibodies. Horseradish peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology Inc.) was used as the secondary antibody for the DAB Detection system (Wuhan Boster Biological Technology, Ltd., Wuhan, China). Antibodies for β-actin (Boster) or total AKT (Cell Signaling Technology Inc.) were used as loading controls.
Materials and methods

Cell
Immunofluorescence and quantitation. At 48 h post-transfection, cells were washed with phosphate-buffered saline, fixed in cold methanol for 10 min at room temperature (RT), and then permeabilized with 0.2% Triton X-100 for 90 min at RT. After washing in PBS and blocking for 30 min in 5% non-fat milk at RT, cells were incubated with rabbit anti-PTEN (1:200) antibody (Santa Cruz Biotechnology Inc.) at 4˚C overnight. After three washes, the secondary antibody fluorescein isothiocyanate-conjugated sheep-anti-rabbit IgG (Santa Cruz Biotechnology Inc.) was added for 1 h at RT. Cells were then analyzed on a microplate reader (Fluoroskan Ascent FL; Thermo Fisher Scientific, Waltham, MA, USA) and images were captured by inverted fluorescence microscopy (TCS SP2; Leica Microsystems, Wetzlar, Germany).
Cell proliferation assay. Cell proliferation was measured with the Cell Counting kit-8 (CCK8) assay (Beyotime Biotechnology) according to the manufacturer's instructions. Briefly, transfected cells were harvested at 10 h and plated in 96-well plates at a density of 3,000 cells/well for each treatment condition. At 24, 48, 72 and 84 h after transfection, 10 µl WST-8 dye (Beyotime Biotechnology) was added to each well, then incubated at 37˚C for 1 h, and absorbance (A) was measured at 450 nm using an iMark bio microplate reader (Bio-Rad Laboratories, Inc.). Cell survival was determined as A treated /A control .
Apoptosis analysis. At 72 h post-transfection, cells were harvested, washed with PBS, stained with Annexin V and propidium iodide, and apoptosis was measured by flow cytometry (acquired 10,000 cells/cell; FACSVantage SE; BD Biosciences, Franklin Lakes, NJ, USA) .
Statistical analysis. Data are expressed as the mean ± standard error of the mean. Statistical analysis was performed across multiple groups using analysis of variance (ANOVA) and confirmed between individual groups using Student-Newman-Keul's method. P<0.05 was considered to indicate a statistically significant difference.
Results
VP22 mediates PTEN intercellular trafficking in BT549
cells. The trafficking ability of a fused PTEN-VP22 recombinant protein was measured. PTEN cDNA was fused to the N-terminal of the VP22 cDNA to produce the pcDNA3-PTEN-VP22 fusion protein expression vector.
Expression of the fusion protein was monitored by western blotting. In transiently transfected BT549 cells, a PTEN-null breast carcinoma cell line (3), an anti-PTEN antibody clearly detected the full-length PTEN-VP22 fusion protein at its expected size (~90 kDa), as well as PTEN (~60 kDa) (Fig. 1A) . In pcDNA3-PTEN-VP22 transfected cells, western blotting showed high expression of full-length PTEN-VP22 as well as a truncated product with the molecular weight of PTEN, indicating cleavage of the two proteins.
To investigate the trafficking property of the fusion protein, BT549 cells were transfected with pcDNA3-PTEN-VP22 or pcDNA3-PTEN, and spreading was observed by fluorescence microscopy (Fig. 1B) . The results showed that only a few cells per field were positive 48 h post-transfection with PTEN (Fig. 1B) . By contrast, when cells were transfected with pcDNA3-PTEN-VP22, a larger number of positive cells (Fig. 1B) with a typical VP22 pattern (i.e., primary transfected cells with cytoplasmic and nuclear staining surrounded by recipient cells with nuclear staining) were observed (Fig. 1C) . This phenomenon was confirmed by fluorescence quantitation after immunofluorescence with the anti-PTEN antibody. The results showed that the fluorescence of cells expressing PTEN-VP22 48 h after transfection was 0.927±0.0196 versus 0.558±0.0105 in cells expressing PTEN alone (P<0.001; Fig. 1D ). Therefore, the fusion protein PTEN-VP22 appears to have the same spreading abilities as VP22.
In addition, fluorescence microscopy of the BT549 human breast carcinoma cell line expressing exogenous PTEN or PTEN-VP22 fusion protein revealed fluorescent PTEN or PTEN-VP22 in the cytosolic and nuclear compartments, although PTEN and PTEN-VP22 were predominantly nuclear in localization (Fig. 1B and C) .
VP22 enhances PTEN-mediated antiproliferative activity in BT549 cells.
To determine whether fusion of PTEN to VP22 affected its biological activity, the CCK-8 assay was used to measure the effect on tumor cell proliferation. The results (Fig. 2) showed that addition of VP22 to the C-terminus of PTEN enhanced antiproliferative activity in general. Growth was similar between pcDNA3-VP22 and pcDNA3 transfected cells, indicating that VP22 expression is non-toxic ( Fig. 2A) . Growth was inhibited over time when BT549 cells were treated with 2.5 µg pcDNA3-PTEN or pcDNA3-PTEN-VP22. The CCK-8 assay revealed that pcDNA3-PTEN and pcDNA3-PTEN-VP22 did not inhibit BT549 proliferation 24 h post-transfection. By contrast, pcDNA3-PTEN and pcDNA3-PTEN-VP22 exhibited significant antiproliferative activity at 48, 72, and 84 h compared with pcDNA3-transfected cells (pcDNA3-PTEN, P<0.001 at 48 and 84 h and P<0.01 at 72 h versus pcDNA3 at the same time points; pcDNA3-PTEN-VP22, P<0.001 at 48, 72, and 84 h, versus pcDNA3 at the same time points). Furthermore, the efficacy of pcDNA3-PTEN-VP22 inhibition of proliferation was greater than that of pcDNA3-PTEN (P<0.001 at 48 and 72 h; P<0.05 at 84 h). These results indicated that the conjugation of VP22 to the C-terminus of PTEN may enhance the basal antiproliferative activity in the BT549 breast carcinoma cell line.
To confirm these results, the antiproliferative activity of various doses of PTEN-VP22 at 48 h post-transfection were compared. As shown in Fig. 2B , cell growth was dose-dependent when BT549 cells were treated with 0.5, 1.5, and 2.5 µg pcDNA3-PTEN-VP22 (P<0.001). Thus, addition of VP22 increased the antiproliferative activity of PTEN in PTEN-deficient breast carcinoma cells.
VP22 enhances PTEN-mediated apoptotic induction in BT549 cells.
Previous studies have shown that transduction of the wild-type PTEN gene into cancer cells induces apoptosis (14) (15) (16) . To investigate whether intercellular spread of PTEN-VP22 enhances its apoptotic capacity, apoptotic induction by PTEN-VP22 and PTEN was compared in BT549 cells (Fig. 3) . It was observed that 5 µg pcDNA3-VP22 did not induce apoptosis compared with 5 µg pcDNA3 (the negative control); however, apoptotic rates in cells transfected with 5 µg pcDNA3-PTEN differed significantly from those for the negative control (P<0.001), revealing that transfection of pcDNA3-PTEN induced apoptosis. In addition, a significant increase in apoptosis was detected in cells transfected with 5 µg pcDNA3-PTEN-VP22 versus 5 µg pcDNA3-PTEN (P<0.001), indicating that VP22-mediated spreading of PTEN-VP22 is associated with an enhanced rate of PTEN-mediated apoptosis in BT549 cells.
VP22 enhances PTEN-mediated decreases in the level of phosphorylated AKT.
AKT is activated following phosphorylation by PIPs and AKT phosphorylation is inversely associated with PTEN expression. The correlation between AKT phosphorylation state and PTEN-VP22 expression was investigated in BT549 cells. As expected, levels of phospho-AKT were the same in pcDNA3 and pcDNA3-VP22 transfected cells and the high level of phospho-AKT was abrogated in pcDNA3-PTEN transfected cells, whereas the higher level of phospho-AKT was abrogated in pcDNA3-PTEN-VP22 transfected cells (Fig. 4) . These results suggest VP22-mediated spreading of PTEN-VP22 is associated with decreased expression of phosphorylated AKT.
Discussion
A present limitation of gene therapy is the ability to deliver sufficient quantities of active proteins to target cells. While secreted proteins can overcome this limitation to a certain extent, it is particularly a problem for nonsecreted proteins, such as PTEN as these proteins are only active in the cells that they are initially delivered to. It has been suggested that VP22 fusion proteins may increase distribution through intercellular transport. Thus increased numbers of cells may reach therapeutic steady state, leading to an overall increase in drug efficacy in the target cell population.
Only N-terminal fusion was investigated as the C-terminal extremity of VP22 is essential for cell-to-cell transport (11, 17) . Expression vectors for wild-type PTEN and PTEN-VP22 were constructed and their activities were compared in the PTEN-null BT549 breast carcinoma cell line. Wild-type PTEN protein and high levels of PTEN-VP22 fusion protein expression in vitro were observed (Fig. 1A) ; both proteins were transcriptionally active (Fig. 1B) . The present study shows that VP22 transduces PTEN across the cell membrane, resulting in a wider distribution in the BT549 cells (Fig. 1B and C) . In addition, VP22 does not change the characteristics of PTEN localization in cells, and PTEN-VP22 was predominantly nuclear in localization, which is similar to PTEN (Fig. 1B) . Furthermore, it was demonstrated that this fusion protein is functional and that the PTEN-VP22 gene transfer induces a stronger antiproliferative effect than PTEN alone in a time-and dose-dependent manner in vitro ( Fig. 2A and B) . VP22 did not display toxicity in these experiments ( Fig. 2A) , suggesting that the increased activity is solely due to the transport properties of VP22.
PTEN acts as a phosphatidylinositol phosphatase with a possible role in the phosphatidylinositol 3-kinase (PI3K)/ AKT pathway (5). Introduction of PTEN into PTEN-deficient cells inhibits the activation of AKT, which is a serine-threonine kinase downstream in the PI3K pathway, is involved in proliferative and anti-apoptotic pathways and exhibits tumor suppressive properties (18) . In order to demonstrate how PTEN-VP22 gene transfer could induce this antiproliferative effect, it was evaluated whether higher protein transport levels were correlated with increased apoptotic activity and decreased levels of phosphorylated AKT in BT549 cells. It was observed that PTEN-VP22 transfection enhanced apoptosis relative to PTEN, while VP22 did not alter apoptotic activity (Fig. 3) . These results suggest that PTEN-VP22 can induce apoptosis in BT549 cells and VP22-mediated spreading of PTEN correlates with enhanced apoptosis. PTEN decreased the expression of phospho-AKT; however, the phosphorylation status of AKT was lower in the presence of PTEN-VP22 versus PTEN. The phospho-AKT states of BT549 cells were not altered by VP22 alone (Fig. 4) . Thus, this demonstrated that PTEN-VP22 can effectively block the (PI3K)/AKT pathway and VP22-mediated spreading of PTEN-VP22 is correlated with the enhanced rate of PTEN-mediated decreases in phospho-AKT status and induction of apoptosis in BT549 cells.
In conclusion, VP22-mediated transport of the PTEN tumor suppressor protein could enhance the biological functions of PTEN, providing a strategy for enhancing the efficacy of gene therapy of breast cancer.
